Motixafortide

(Aphexda)

Motixafortide

Drug updated on 11/17/2023

Dosage FormInjection (subcutaneous; 62 mg as a lyophilized powder in a single-dose vial for reconstitution)
Drug ClassHematopoietic stem cell mobilizers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Product Monograph / Prescribing Information